UNICREDIT BANK/CALL/NOVO-NORDISK B/1000/0.2/18.12.24 | Market Closed - BOERSE MUENCHEN 03:46:55 2024-07-11 pm EDT | ||
| 1.98 EUR | -11.61% |
|
| Current month | -24.71% | ||
| 1 month | -21.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.98 | -11.61% |
| 24-07-10 | 2.24 | +5.16% |
| 24-07-09 | 2.13 | -10.50% |
| 24-07-08 | 2.38 | +3.93% |
| 24-07-05 | 2.29 | +4.09% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 03:46 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HC8N38 |
| ISIN | DE000HC8N386 |
| Date issued | 2023-08-14 |
| Strike | 1,000 kr |
| Maturity | 2024-12-18 (160 Days) |
| Parity | 5 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.13 € |
| Spread % | 6.37% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.11%
- Stock Market
- Warrants
- Warrant
